Carvedilol (cas 72956-09-3) blockage of delayed rectifier Kv2.1 channels and its molecular basis
-
Add time:07/14/2019 Source:sciencedirect.com
Previous studies indicated that one of the action targets of Carvedilol (cas 72956-09-3) is the voltage-gated potassium (Kv) channel, which has a fundamental role in the control of electrical properties in excitable cells. It is not clear whether this compound exerts any actions specifically on delayed rectifier Kv2.1 channels. The present study is conducted on Kv2.1 currents heterologously expressed in HEK293 cells to characterize the block by carvedilol in detail, identifying molecular determinants and providing biophysical insights of the block. Macroscopic Kv2.1 currents obtained by whole-cell recording were substantially inhibited after addition of carvedilol with an IC50 value of 5.1 μM. This drug also led to a largely hyperpolarizing shift (30 mV) of the inactivation curve, which may contribute to the blocking action due to more inactivation of Kv2.1 currents occurred in depolarization potentials. Mutations at Y380 (a putative TEA binding site) and K356 (a K+ binding site) in the outer vestibule of Kv2.1 channels significantly eliminated the inhibitory effects of carvedilol and prevented the leftward shift of inactivation. Moreover, mutations at above positions modulated the effects of carvedilol on the deactivation but not activation kinetics of Kv2.1 channels. Collected data indicate that carvedilol can exert a blocking effect on the closed-state of Kv2.1 channels, and specific residues within the S5–P and P–S6 linkers in the outer vestibule may play crucial roles in carvedilol-induced blocking for Kv2.1 channels.
We also recommend Trading Suppliers and Manufacturers of Carvedilol (cas 72956-09-3). Pls Click Website Link as below: cas 72956-09-3 suppliers
Prev:The adrenergic receptor antagonist Carvedilol (cas 72956-09-3) interacts with serotonin 2A receptors both in vitro and in vivo
Next:The cardioprotective effects of Carvedilol (cas 72956-09-3) on ischemia and reperfusion injury by AMPK signaling pathway) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Enhancement of oral bioavailability of poorly water soluble Carvedilol (cas 72956-09-3) by chitosan nanoparticles: Optimization and pharmacokinetic study07/22/2019
- Solidification of Carvedilol (cas 72956-09-3) loaded SMEDDS by swirling fluidized bed pellet coating07/20/2019
- Prophylactic use of Carvedilol (cas 72956-09-3) to prevent ventricular dysfunction in patients with cancer treated with doxorubicin07/21/2019
- Carvedilol (cas 72956-09-3) attenuates experimentally induced silicosis in rats via modulation of P-AKT/mTOR/TGFβ1 signaling07/19/2019
- Carvedilol (cas 72956-09-3) and thyroid hormones co-administration mitigates oxidative stress and improves cardiac function after acute myocardial infarction07/18/2019
- Comparative study of Carvedilol (cas 72956-09-3) and quinidine for inhibiting hKv4.3 channel stably expressed in HEK 293 cells07/17/2019
- Soluplus®, Eudragit®, HPMC-AS foams and solid dispersions for enhancement of Carvedilol (cas 72956-09-3) dissolution rate prepared by a supercritical CO2 process07/16/2019
- The cardioprotective effects of Carvedilol (cas 72956-09-3) on ischemia and reperfusion injury by AMPK signaling pathway07/15/2019
- The adrenergic receptor antagonist Carvedilol (cas 72956-09-3) interacts with serotonin 2A receptors both in vitro and in vivo07/13/2019
-
Health and Chemical more >
-
Related Products